CJC-1295 with DAC — long-acting GHRH analog via albumin conjugation
In short
GHRH analog with a DAC complex, studied for prolonged growth hormone release via albumin binding.
Overview
CJC-1295 with DAC (Drug Affinity Complex) is a modified version of growth hormone releasing hormone () engineered for extended duration. The addition of DAC technology extends the half-life to 6-8 days, providing continuous growth hormone elevation rather than pulsatile release. This long-acting formulation offers convenience but differs significantly from natural
DAC technology binds to albumin, extending half-life to 6-8 days and providing continuous receptor stimulation
Molecular information
Research indications
Grouped by area. Each entry reflects a separate published hypothesis or clinical signal - not medical advice.
DAC version provides stable levels, but disrupts native pulsatile pattern - tradeoff for chronic vs physiological research.
Injection-site reaction
common
Transient flushing
uncommon
Water retention (more pronounced with DAC)
common
Mild hunger
uncommon
3 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Teichman - DAC kinetics
Phase 1 | 30-250 mcg/kg | single | Half-life 6-8 days, prolonged IGF-1 elevation
J Clin Endocrinol Metab · 2006
View the studyInformation about CJC-1295 with DAC is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadNo comments yet. Be the first.
Comments are reviewed before publishing.
